Keystone Symposia: Antibody-based therapeutics for cancer

Bibliography

• HUDSON PJ, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 9(1):129–134.
   PubMed Web of Science ®Google Scholar
• PRESTA LG: Engineering antibodies for therapy. Curt: Pharm. Biotechnol (2002) 3(3):237–256.
   PubMedGoogle Scholar
• TRCKA J, MOROI Y, CLYNES RA et al.: Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity (2002) 16(6):861–868.
   PubMed Web of Science ®Google Scholar
• CRAGG MS, MORGAN SM, CHAN HT et al.: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2003) 1O1(3):1045–1052.
   Google Scholar
• DDECHANT M, VIDARSSON G, STOCKMEYER B et al.: Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood (2002) 100(13):4574–4580.
   PubMed Web of Science ®Google Scholar
• GARRETT TP, MCKERN NM, LOU M et al.: The crystal structure of a truncated ErbB2 ectodomain reveals an activeconformation, poised to interact with otherErbB receptors. Ma Cell (2003) 11(2):495–505.
   PubMed Web of Science ®Google Scholar
• LYNCH DH, YANG XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment.Semin. °flea (2002) 29(1 Suppl. 4):47–50.
   Google Scholar
• RANSON M, SLIWKOWSKI MX: Perspectives on anti-HER monoclonal antibodies. Oncology (2002)63\(Suppl. 1):17–24.
   Google Scholar
• PEGRAM MD, REESE DM: Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin. °flea (2002) 29(3 Suppl. 11):29–37.
   Google Scholar
• CARMICHAEL JA, POWER BE, GARRETT TP et al.: The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Ma Biol. (2003) 326(2):341–351.
   Google Scholar
• VON MEHREN M, ADAMS GP, WEINER LM: Monoclonal antibody therapy for cancer. Anna. Rev Med. (2003) 54:343–369.
   PubMed Web of Science ®Google Scholar
• EWERT S, HUBER T, HONEGGER A, PLUCKTHUN A: Biophysical properties of human antibody variable domains. I Ma Biol. (2003) 325:531–553.
   PubMed Web of Science ®Google Scholar
• KOHL A, BINZ HK, FORRER P et al.: Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc. Natl. Acad. Sci. USA (2003) 100(4):1700–1705.
   PubMed Web of Science ®Google Scholar
• NIELSEN UB, KIRPOTIN DB, PICKERING EM et al.: Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta(2002) 1591(1-3):109–118.
   PubMed Web of Science ®Google Scholar
• MILLER JC, ZHOU H, KWEKEL J et al.: Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers.Proteomics (2003) 3(1):56–63.
   PubMed Web of Science ®Google Scholar
• VRUDHULA VM, KERR DE,SIEMERS NO, DUBOWCHIK GM, SENTER PD: Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-Lactamase fusion protein. Bioorg. Med. Chem. Lett. (2003) 13(3):539–542.
   PubMed Web of Science ®Google Scholar
• NIETHAMMER AG, XIANG R, BECKER JC et al.: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.Nat. Med. (2002) 8(12):1369–1375.
   Google Scholar
• RADER C, POPKOV M, NEVES JA, BARBAS CF 3RD: Integrin alpha(v)beta3targeted therapy for Kaposi's sarcoma with an M vitro evolved antibody. FASEB(2002) 16(14):2000–2002.
   PubMedGoogle Scholar
• FRANCIS RJ, SHARMA SK,SPRINGER C et al.: A Phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. Cancer (2002) 87(6):600–607.
   Google Scholar
• SMALLSHAW JE, GHETIE V, RIZO J et al.: Genetic engineering of an immunotwdn to eliminate pulmonary vascular leak in mice. Nat. Biotech.(2003) 21: DOI 10.1038/nbt800.
   Google Scholar
• ICHINOSE M, LIU XH, HAGIHARA N, YOULE RJ: Extracellular Bad fused to toxin transport domains induces apoptosis.Cancer Res. (2002) 62(5):1433–1438.
   PubMed Web of Science ®Google Scholar
• VAN BEIJNUM JR, MOERKERK PT, GERBERS AJ et al.: Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int. Cancer (2002) 101(2):118–127.
   PubMed Web of Science ®Google Scholar
• DER MAUR AA, ZAHND C, FISCHER F et al.: Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework.i. Biol. Chem.(2002) 277(47):45075–45085.
   Google Scholar
• TSE E, LOBATO MN, FORSTER A, TANAKA T, CHUNG GT,RABBITTS TH: Intracellular antibody capture technology: application to selection of intracellular antibodies recognising theBCR-ABL oncogenic protein. I Ma Biol.(2002) 317(1):85–94.
   PubMed Web of Science ®Google Scholar
• BAI J, SUI J, ZHU RY et al: Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. Biol. Chem. (2003) 278(3):1433–1442.
   Web of Science ®Google Scholar
• SHARKEY RM, MCBRIDE WJ, KARACAY H et al.: A universal pretargetingsystem for cancer detection and therapy using bispecific antibody. Cancer Res.(2003) 63(2):354–363.
   PubMed Web of Science ®Google Scholar
• SANTIMARIA M, MOSCATELLI G, VIALE GL et al.: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clio. Cancer Res. (2003) 9(2):571–579.
   PubMed Web of Science ®Google Scholar
• WARREN TL, WEINER GJ: Synergism between cytosine-guanine ofigodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Sernin. Oncel (2002) 29(1 Suppl. 2):93–97.
   Google Scholar
• REARDON DA, AKABANI G, COLEMAN RE et al.: Phase II trial of murine (131)1-labeled antitenascin monoclonal antibody 8106 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Clio. Oncel (2002) 20(5):1389–1397.
   Web of Science ®Google Scholar